Targeting EGFRvIII for treatment of glioblastoma: From molecular mechanisms to clinical strategies.
10.11817/j.issn.1672-7347.2019.180643
- Author:
Songming CHEN
1
;
Xuejun LI
2
Author Information
1. Xiangya School of Medicine, Central South University, Changsha 410013, China.
2. Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, China.
- Publication Type:Journal Article
- MeSH:
Brain Neoplasms;
Cell Line, Tumor;
ErbB Receptors;
Glioblastoma;
drug therapy;
Humans;
Signal Transduction
- From:
Journal of Central South University(Medical Sciences)
2019;44(11):1281-1286
- CountryChina
- Language:Chinese
-
Abstract:
Glioblastoma is one of the most common intracranial malignant tumor and its initiation and progression are closely associated with epidermal growth factor receptor (EGFR). EGFR variant III (EGFRvIII) is a mutant EGFR and highly expressed in glioblastoma. EGFRvIII promotes the proliferation and invasiveness of glioblastoma cells and induces drug resistance by signaling networks.
